AstraZeneca Board Rejects Latest Pfizer Offer
AstraZeneca rejects $106 billion offer; Pfizer states its case for the merger with British government.
AstraZeneca board of directors rejected the latest $106 billion acquisition proposal from Pfizer, reporting in a statement that the terms are “inadequate, substantially undervalue AstraZeneca, and are not a basis on which to engage with Pfizer.”
The board noted that the a large proportion of the consideration payable in Pfizer shares and the tax-driven inversion structure remain unchanged from earlier proposals and were reasons for rejecting the proposal. In addition, Leif Johansson, chairman of AstraZeneca, reiterated the company’s plans for investment and growth and advised shareholders to take no action.
“AstraZeneca continues to invest significantly in research, development and manufacturing in the U.K., Sweden and the U.S. We are showing strong momentum as an independent company, in particular with our exciting, rapidly progressing pipeline, which the Board believes will deliver significant value for shareholders,” Johansson said in a statement. “Pfizer’s proposal would dramatically dilute AstraZeneca shareholders’ exposure to our unique pipeline and would create risks around its delivery. As such, the Board has no hesitation in rejecting the proposal.”
Industry analysts indicated that Pfizer may take the route of a hostile takeover. The takeover would be the largest acquisition of a British company by a foreign business. In a letter to British Prime Minister David Cameron, Pfizer Chairman and CEO Ian Read outlining commitments the company would make as part of the acquisition, including the completion of the planned AstraZeneca Cambridge campus, establishing the company’s corporate and tax residence in England, and basing other operations in the United Kingdom.
Pfizer’s May 2, 2014 Offer StatementAstraZeneca’s May 2, 2014 Response
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Novartis Acquisition of Regulus Therapeutics is Complete
June 25th 2025A key property included in the acquisition is farabursen, an investigational next-generation oligonucleotide targeting the microRNA miR-17 with preferential kidney exposure, intended to treat people with autosomal dominant polycystic kidney disease.
